Bio-Sourcing and Afrigen Biologics Collaborate on Innovative Biomanufacturing Platform to Expand Biotherapeutic Accessibility in South Africa
Wednesday, June 05, 2024
Belgian biotech firm Bio-Sourcing and South African company Afrigen Biologics have formed a promising collaboration to pioneer a groundbreaking project in South Africa centered around Bio-Sourcing's revolutionary biotherapeutic platform, BioMilk™.
BioMilk™ holds immense promise in redefining medical solutions globally, offering novel therapeutics like monoclonal antibodies (mAbs) and insulin products to address critical medical needs. The collaboration aims to establish a joint venture in South Africa to spearhead this initiative, with interest already expressed by public funding agencies and potential investors.
Afrigen Biologics brings to the table their expertise in mRNA vaccine technology from Cape Town, complementing Bio-Sourcing's innovative BioMilk™ technology, which enables streamlined production of cutting-edge biopharmaceuticals including Active Pharmaceutical Ingredients (APIs) within South Africa.
The current scenario in South Africa sees high-priced imports of biotherapeutics, rendering them inaccessible to many patients. This collaboration not only seeks to bolster the nation's pharmaceutical independence but also endeavors to significantly slash production costs, thereby enhancing the affordability and availability of vital medicines in oncology and autoimmune diseases.
Bio-Sourcing, expressed his enthusiasm about this partnership, emphasizing its potential to revolutionize healthcare delivery in Africa. He anticipates the inauguration of the first production facility and eagerly looks forward to supplying essential medicines to South Africa and other African nations, thereby addressing critical patient needs.
Source: businesswire.com
